Jakub Hlavka

Title(s)Research Assistant Professor
Phone+1 213 821 6113
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Pardee RAND Graduate School, Santa Monica, CAPhDPublic Policy Analysis: Health Economics
    Georgetown University , Washington D.C.MA International Affairs, Technology Policy
    University of Economics, Prague, Czech RepublicBSc.International Trade
    Collapse Awards and Honors
    Aspen Institute Central Europe2017Aspen Young Leader
    St Gallen Symposium2015Leader of Tomorrow

    Collapse Overview 
    Collapse Overview
    Jakub Hlávka, PhD, is a Research Assistant Professor in the Health Policy and Management Department of the Price School of Public Policy and Schaeffer Center for Health Policy & Economics, University of Southern California. His research interests include innovative payment for healthcare, health system reform, emerging therapies and the study of inequality.

    Prof. Hlávka completed his PhD at the Pardee RAND Graduate School where he studied innovative payment approaches for emerging treatments like cell and gene therapies, specializing in cardiovascular conditions. At RAND, he also co-authored studies in national security, aerospace and emerging technologies and has served in research and consulting roles at the intersection of research finance, intellectual property, national security and governance at Genentech, the Fraunhofer Society, RAND Europe, Czech Government and the Czech Ministry of Finance. Dr. Hlávka holds degrees from Georgetown University and the University of Economics in Prague.

    Prof. Hlávka teaches graduate-level health economics at the Sol Price School of Public Policy at USC.

    Collapse ORNG Applications 
    Collapse Websites
    Collapse In The News
    Collapse Faculty Mentoring

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Hlávka JP, Mattke S, Wilks A. The Potential Benefits of Deferred Payment for a Hypothetical Gene Therapy for Congestive Heart Failure: A Cost-Consequence Analysis. Appl Health Econ Health Policy. 2020 Feb 24. PMID: 32090302.
      View in: PubMed
    2. Hlavka JP, Mattke S, Liu JL. Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer's Treatment. Rand Health Q. 2019 May; 8(3):2. PMID: 31205802.
      View in: PubMed
    3. Mulcahy AW, Hlavka JP, Case SR. Biosimilar Cost Savings in the United States: Initial Experience and Future Potential. Rand Health Q. 2018 Mar; 7(4):3. PMID: 30083415.
      View in: PubMed
    4. Erik Snowberg Dana P. Goldman, Karen Van Nuys, Wei-Han Cheng, Jakub P. Hlávka, Luca Pani, Sylvain Chassang .A New Model for Pricing Drugs of Uncertain Efficacy. NEJM Catalyst. 2018.
    5. Andrew W Mulcahy, Kandice Kapinos, Brian Briscombe, Lori Uscher-Pines, Ritika Chaturvedi, Spencer R Case, Jakub Hlávka, Benjamin M Miller.Toward a Sustainable Blood Supply in the United States. 2016.